`ASSOCIATE
`
`(202) 772-8787
`MBODENSTEIN@SKGF.COM
`
`May 26, 2015
`
`Commissioner for Patents
`
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`
`
`
`
`<.flit/111111V,.I
`
`Con trmation No. I 091
`
`Art Unit 1628
`
`Re: US Track 1 Patent Application
`Appl. No. 14/500,409; Filed: September 29, 2014
`For:
`Buprenorphine—Wafer for Drug Substitution Therapy
`Inventors: OKSCHE et al.
`
`Our Ref: 1861.2700001/JMC/MSB
`
`Commissioner:
`
`Transmitted herewith for appropriate action are the following documents:
`
`1. Online Credit Card Payment Authorization in the amount of $160.00 to cover:
`
`$160.00 Terminal Disclaimer fee.
`
`2. Terminal Disclaimer;
`
`3. Declaration under 37 C.F.R. § 1.132; and
`
`4. Amendment and Reply Under 37 C.F.R. §l.l l l.
`
`The above-listed documents are filed electronically through EFS- Web.
`
`In the event that extensions of time are necessary to prevent abandonment of this patent
`application, then such extensions of time are hereby petitioned for.
`
`The US. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
`or credit any overpayment, to our Deposit Account No. 19-0036.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`
`Attorney for Applicants
`Registration No. 58,885
`
`MSB/lds
`
`Enclosures
`
`
`
`200571371.DOCX
`
`